Parkinson's Disease Related Research Tools
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Pathologically, PD is characterized by the presence of abnormal intra-neuronal aggregates of α-synuclein (SNCA). SNCA is central to the pathogenesis of PD, as is highlighted by the fact that rare SNCA mutations, duplications, or triplications cause autosomal dominant familial PD. The etiology of idiopathic PD is multifactorial, likely arising from a combination of polygenic inheritance, environmental exposures, and gene-environment interactions. The current medical management of PD aims at controlling signs and symptoms as long as possible while minimizing adverse effects. Most of them are targeting at supplementation of dopamine to the brain to alleviate motor dysfunction caused by the degeneration of dopaminergic neurons in the nigrostriatal system.
Numerous potential therapies for PD are at various stages of preclinical and clinical testing. These agents target many aspects of PD pathogenesis. Several basic pathophysiological pathways are depicted in Fig.1, including those that lead to Lewy bodies, and those involving inflammatory factors, mitochondrial dysfunction and oxidative stress.
Genetic-based targeted therapies currently being tested in PD patients focus on SNCA, glucocerebrosidase (GBA), and leucine-rich repeat kinase (LRRK2). Multiple lines of evidence support a pivotal role of SNCA in PD pathogenesis. The presence of aggregated α-synuclein in specific brain regions suggests a central role for this protein in sporadic disorder. Heterozygous GBA mutations increase the risk of developing PD and other synucleinopathies. GBA mutations are the most frequent genetic risk factors for PD identified to date, with 7% to 10% of PD patients carrying at least 1 of approximately 300 reported GBA mutations. LRRK2 interacts with many key proteins implicated in PD, suggesting that LRRK2 may be a central player in the pathways underlying disease pathogenesis. The current leading hypothesis shows that increased kinase activity by LRRK2 mutations is responsible for PD. The popular targets in PD researches are listed below:
| SNCA | GBA | PINK1 | LRRK2 |
| CYP2D6 | PRKN | VPS35 | PARK7 |
Creative Biolabs offers comprehensive products as well as high-quality customized services for various targets involved in the signaling pathway for PD research. For any customized services or products, please feel free to contact us for more information.
Parkinson's Disease Assay ServiceTarget
Loading...
NeuroPro™ Anti-GDNF BBB Shuttle Protein [CAT#: NRZP-0423-ZP509]
- Species:
- Human
- Relevant Diseases:
- Parkinson's Disease
NeuroPro™ Anti-GDNF BBB Shuttle Protein [CAT#: NRZP-0423-ZP500]
- Species:
- Human
- Relevant Diseases:
- Parkinson's Disease
Alpha-Synuclein Aggregation Assay Kit [CAT#: NRZP-1122-ZP37]
Alpha Synuclein Aggregation Kit [CAT#: NRZP-1122-ZP15]
This kit is designed for an accurate quantitative measurement of alpha synuclein aggregation in brain extracts.
iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) [CAT#: NAB-08-PZ735]
Rabbit Monoclonal Antibody to LRRK2
- Host Species:
- Rabbit
- Species Reactivity:
- Mouse; Human
- Applications:
- ICC; IF; IHC-P; WB
- Conjugation:
- Unconjugated; APC; PE; HRP; Biotin; FITC
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.
- Applications:
- Gene Silencing
- Applications:
- Inhibits PINK1 expression to study its role in mitochondrial quality control, mitophagy, and neuronal survival in PD. Facilitates research on PINK1-mediated pathways for neuroprotection. Suitable for in vitro (mitochondrial stress assays) and in vivo (PINK1 mutant mouse models).
- Applications:
- Modulates DJ-1 expression to investigate its role in oxidative stress response, mitochondrial function, and dopaminergic neuron survival in PD. Enables studies on DJ-1's protective mechanisms against neurodegeneration. Ideal for in vitro (neuroblastoma cell lines) and in vivo (DJ-1 knockout mouse models).
- Applications:
- Targets SNCA mRNA to decrease α-synuclein aggregation in PD and dementia with Lewy bodies (DLB). Facilitates studies on α-synuclein's role in synaptic toxicity, mitochondrial dysfunction, and neuroinflammation. Suitable for in vitro (dopaminergic neuron cultures) and in vivo (PD mouse models) research.
- Applications:
- Reduces LRRK2 expression to study its role in neuronal autophagy, mitochondrial dysfunction, and dopaminergic neurodegeneration in Parkinson's disease (PD). Enables preclinical evaluation of LRRK2 inhibition for neuroprotection. Optimized for in vivo PD models (e.g., α-synuclein transgenic mice).
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Epilepsy; Parkinson's Disease
- Relevant Diseases:
- Alzheimer's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- Relevant Diseases:
- Parkinson's Disease
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-Alpha Synuclein Antibody (NRP-0422-P614) (Cat#: NRP-0422-P614)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
